Jerome Durivault

Monaco, 98000, Monaco

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapies.

Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapies.

Journal: Scientific reports

Published: October 20, 2025

Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors.

Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 17, 2025

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Journal: Theranostics

Published: September 16, 2025

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.

Journal: Current oncology (Toronto, Ont.)

Published: September 20, 2024

Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.

Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.

Journal: Experimental dermatology

Published: August 26, 2024

De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.

De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.

Journal: Cancer research

Published: April 30, 2024

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 13, 2023

Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance.

Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance.

Journal: Cancer research communications

Published: July 12, 2023

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

Journal: Molecular oncology

Published: December 04, 2022

Metabolic Rewiring toward Oxidative Phosphorylation Disrupts Intrinsic Resistance to Ferroptosis of the Colon Adenocarcinoma Cells.

Metabolic Rewiring toward Oxidative Phosphorylation Disrupts Intrinsic Resistance to Ferroptosis of the Colon Adenocarcinoma Cells.

Journal: Antioxidants (Basel, Switzerland)

Published: November 08, 2022

'Warburg effect' controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives.

'Warburg effect' controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives.

Journal: Seminars in cancer biology

Published: April 30, 2022

Genetic Disruption of the γ-Glutamylcysteine Ligase in PDAC Cells Induces Ferroptosis-Independent Cell Death In Vitro without Affecting In Vivo Tumor Growth.

Genetic Disruption of the γ-Glutamylcysteine Ligase in PDAC Cells Induces Ferroptosis-Independent Cell Death In Vitro without Affecting In Vivo Tumor Growth.

Journal: Cancers

Published: March 23, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026